UK NHS faces drug shortages

Generics/General | Posted 27/05/2022 post-comment0 Post your comment

The United Kingdom’s (UK) National Health Service (NHS) faces shortages of blood pressure pills, painkillers and antidepressants due to drug manufacturer supply problems.

Drug shortages 3 V13k14

It has been reported that many drug producers are tackling the rising costs of raw materials, in combination with approval delays of up to 18 months from the medicines regulator. However, the UK’s Medicines and Healthcare products Regulatory Agency has stated that it regularly accelerates approval processes where products could be subject to shortage.

The UK is already in the midst of a hormone replacement therapy (HRT) drug crisis, and it now appears that dozens of other medications may also soon be in scant supply. Some figures indicate that there are up to 50 generic medicines used by the NHS that are having supply issues, with most of these leaving patients with no alternative treatment options.

The UK’s Pharmaceutical Services Negotiating Committee has reported that 67 drugs have been added to a list that the UK Government is willing to pay a higher price due to problems such as supply issues. In addition, the Association of Independent Multiple Pharmacies in the UK, has reported that at least half a million patients are likely to be affected by this possible drug supply crisis.

Drug supply issues have also been reported in other regions of the world. For example, in Japan, supply issues are resulting from the shutdown of several medicines manufactures [1]. In Europe, drug shortages are due to a combination of manufacturing problems, industry quotas, legal parallel trade and pricing issues, and have been exacerbated by issues surrounding the COVID-19 pandemic [1]. In Australia, the government has introduced a new bill to address drug shortages [2].

Related articles
UK pharmacists gain powers to address drug shortages

Australia’s TGA publishes protocol to address drug shortages


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View last week’s headline article: Nomenclature of biologicals and biosimilars in Peru

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de la semana pasada: Nomenclature of biologicals and biosimilars in Peru

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Drug shortages hit Japan and Europe []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 May 27]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Australia introduces new bill to address drug shortages []. Mol, Belgium: Pro Pharma Communications International; [cited 2022 May 27]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Generic drug growth in Brazil and Venezuela
53 MD002445
Generics/General Posted 15/09/2023
Pharmaceutical manufacturing companies in Brazil
91 AA007225
Generics/General Posted 26/08/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010